Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 5Not yet recruiting 2Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Breast Neoplasms 471Neoplasms 328Colorectal Neoplasms 235Carcinoma, Non-Small-Cell Lung 234Lung Neoplasms 200Prostatic Neoplasms 179Carcinoma, Hepatocellular 174Stomach Neoplasms 138Pancreatic Neoplasms 126Leukemia, Myeloid, Acute 114Uterine Cervical Neoplasms 110Rectal Neoplasms 105Multiple Myeloma 94Recurrence 89Squamous Cell Carcinoma of Head and Neck 84Head and Neck Neoplasms 79Neoplasm Metastasis 76Ovarian Neoplasms 75Brain Neoplasms 71Colonic Neoplasms 68Glioblastoma 67Esophageal Neoplasms 66Triple Negative Breast Neoplasms 65Endometrial Neoplasms 58Precursor Cell Lymphoblastic Leukemia-Lymphoma 56Small Cell Lung Carcinoma 54Disease 54Motor Activity 53Hematologic Neoplasms 53Glioma 48

Interventions

disitamab vedotin 1Trastuzumab 1Tegafur 1Oxaliplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × OTHER × HER2-positive Gastric Cancer × Clear all
NCT06492317 2024-07-09

RC48 Plus AK104 as First-line Treatment for HER2-overexpressing Advanced Gastric Cancer

The First Affiliated Hospital of Zhengzhou University

Phase 2 Not yet recruiting
20 enrolled
Gastrointestinal

HER2-positive Gastric Cancer

NCT06439550 2024-06-03

Adjuvant Treatment With Serplulimab,Trastuzumab and SOX in the HER-2 Positive GC/GEJC

The First Affiliated Hospital of Zhengzhou University

Phase 2 Not yet recruiting
42 enrolled
Gastrointestinal

HER2-positive Gastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡